ADXS31142 Immunotherapy ± Pembrolizumab Treatment for Metastatic Castration-Resistant Prostate Cancer: Open-Label Phase I/II KEYNOTE-046 Study

BACKGROUND: ADXS31-142 is an attenuated Listeria monocytogenes-based immunotherapy targeting prostate-specific antigen (PSA), being evaluated as monotherapy and combined with pembrolizumab for metastatic castration-resistant prostate cancer (mCRPC). PATIENTS AND METHODS: The 2-part phase I/II KEYNOT...

Descripción completa

Detalles Bibliográficos
Autores principales: Stein, Mark N, Fong, Lawrence, Tutrone, Ronald, Mega, Anthony, Lam, Elaine T, Parsi, Megan, Vangala, Surya, Gutierrez, Andres A, Haas, Naomi B
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Genitourinary Cancer
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9177110/
https://www.ncbi.nlm.nih.gov/pubmed/35373299
http://dx.doi.org/10.1093/oncolo/oyac048

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9177110/
https://www.ncbi.nlm.nih.gov/pubmed/35373299
http://dx.doi.org/10.1093/oncolo/oyac048

Ejemplares similares